Fusion of the peptide to the proteoglycan decorin, a TGF-β inhibitor, resulted in a skin-homing therapeutic that inhibited TGF-β signaling in skin and significantly improved the survival of recessive dystrophic epidermolysis bullosa mice. This evidence concerns the gene TGFB1 and recessive dystrophic epidermolysis bullosa.